Heather Turner - Lyell
bm-navigation: bm-t3-home-navigation
bm-pageheader: bm-t3-pageheader

Heather Turner

Chief General Counsel

Heather Turner

Heather brings to Lyell almost 20 years of legal guidance to private and public biotechnology companies.  She also brings deep cell therapy experience and broad strategic capabilities.

She has managed portfolio strategy, project teams, medical affairs, HR, government affairs and facilities. Prior to joining Lyell, she was most recently Executive Vice President, General Counsel and Secretary of Sangamo Therapeutics, Inc. where she guided the company in equity financings and the acquisition of a publicly traded French company.  Prior to Sangamo, Heather most recently served as Head of Portfolio Strategy and Executive Vice President at Atara Biotherapeutics, Inc. where she was responsible for multiple functions in addition to Legal. She was also General Counsel and Secretary of Orexigen Therapeutics, Inc. where she led various G&A functions including legal, human resources, risk management, compliance and facilities. She has an extensive experience involving public reporting, compliance and disclosure issues, as well as broad knowledge and experience in negotiating and structuring commercial relationships including distribution, manufacturing, supply and clinical trial agreements. Heather started her career at Cooley LLP where she advised public and private companies, investors and board members.

Heather is a member of the State Bar of California and holds a BA from U.C. Santa Barbara and a Juris Doctor degree from University of California Los Angeles School of Law.